U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07093411) titled 'Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma' on July 14.
Brief Summary: A phase I, open-label clinical study to evaluate the safety, tolerability, and efficacy of LUCAR-E9D,LUCAR-E9K, a dual-targeted cell preparation targeting CD19/CD20, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
B-cell Non-Hodgkin Lymphoma Recurrent B-cell Non-Hodgkin Lymphoma Refractory
Intervention:
BIOLOGICAL: LUCAR-E9D or LUCAR-E9K cells product
Prior to infusion of the LUCAR-E9D or LUCAR-E9K cells product ...